Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Sobi™) announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need that impact more than 275,000 patients globally.